Home/Filings/4/0001722482-22-000061
4//SEC Filing

Brophy Gerard 4

Accession 0001722482-22-000061

CIK 0001722482other

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 9:32 PM ET

Size

10.7 KB

Accession

0001722482-22-000061

Insider Transaction Report

Form 4
Period: 2022-02-23
Brophy Gerard
EVP, Biopharma Production
Transactions
  • Award

    Stock Options (Right to Buy)

    2022-02-23+43,70843,708 total
    Exercise: $33.09Exp: 2032-02-23Common Stock (43,708 underlying)
  • Sale

    Common Stock

    2022-02-23$33.79/sh3,059$103,364125,181 total
  • Award

    Common Stock

    2022-02-23+15,110140,291 total
  • Tax Payment

    Common Stock

    2022-02-25$35.39/sh2,043$72,302138,248 total
Footnotes (5)
  • [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.75 to $33.94 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
  • [F3]Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023.
  • [F4]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's.
  • [F5]Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023.

Issuer

Avantor, Inc.

CIK 0001722482

Entity typeother

Related Parties

1
  • filerCIK 0001776107

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 9:32 PM ET
Size
10.7 KB